Lunit teams up with Discovery Life Sciences to sell AI pathology to biopharma

Lunit, the Seoul-listed cancer AI company, announced on 12 October 2026 a strategic collaboration with Discovery Life Sciences, a biospecimen and specialty laboratory provider, to place its Lunit SCOPE pathology software inside Discovery's biomarker and tissue analysis services for drug developers ¹. No financial terms were disclosed ¹.

What the agreement covers

The two companies will work with biopharma clients to run Lunit SCOPE within Discovery's laboratory workflows, adjusting the AI analysis to the design of each programme ¹. Discovery sources the tissue, processes it and performs the pathology in its own laboratories, with the AI applied at the point of analysis ¹. The stated aim is to give pharmaceutical and biotechnology companies standardised, quantitative tissue data for clinical research, translational studies and drug development ¹. The companies also plan to expand AI-enabled tissue analysis services intended to improve the reproducibility of tissue-based work ¹.

Discovery brings scale in the trial market. It says it has more than 25 years of assay experience, has delivered biomarker services for more than 2,000 clinical trial programmes and currently supports over 350 active ones ¹. Lunit, founded in 2013, says its products are used at over 10,000 sites in more than 65 countries, and that Lunit SCOPE is already used in research partnerships with pharma and laboratory companies for biomarker research and companion diagnostic development ¹.

Anna Juncker-Jensen, vice president of scientific affairs at Discovery, argued that "AI-powered pathology only delivers on its promise when the tissue and the workflow behind it are consistent" ¹. Lunit chief executive Brandon Suh said "AI-powered pathology is becoming an essential part of modern translational research" ¹.

What it means for the market

The deal is a distribution play. Rather than selling software licence by licence to sponsors, Lunit gains a channel through a service provider that already sits inside hundreds of live trial programmes ¹. For pharma and biotech buyers, the offer is a single vendor for specimens, processing and AI readout, which removes one integration step when commissioning biomarker work ¹. For Discovery, adding a named AI product gives it a quantitative pathology layer to sell alongside its existing molecular pathology, genomics, proteomics and flow cytometry services ¹.

The release follows other Lunit tie-ups listed on its newsroom, including a collaboration with 10x Genomics to combine AI pathology analysis with spatial molecular data for oncology research ¹. That points to a strategy of reaching drug developers through established laboratory and tools companies rather than alone.

What the announcement does not say matters for investors. There is no revenue figure, no contract value, no named biopharma client and no target for how many programmes will use the software ¹. The scale of the opportunity therefore rests on Discovery's own trial counts rather than on committed demand.

Caveats

The only source is the companies' own announcement, and its forward-looking aims, such as broader global access and faster evidence generation, are expectations rather than results ¹. No data on accuracy or reproducibility gains from the combined service were published ¹. The next public step is Lunit's appearance at Discovery's B4 Tour event in South San Francisco on 14 October, where Lunit Oncology medical director Yoojoo Lim is due to speak on AI in biomarkers ¹.